433 related articles for article (PubMed ID: 16956305)
1. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Bernard-Marty C; Lebrun F; Awada A; Piccart MJ
Drugs; 2006; 66(12):1577-91. PubMed ID: 16956305
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
Simonds HM; Miles D
Expert Opin Biol Ther; 2007 Apr; 7(4):487-91. PubMed ID: 17373900
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody-based targeted therapy in breast cancer.
Altundag K; Esteva FJ; Arun B
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):99-106. PubMed ID: 15777217
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of chemotherapy by anti-HER.
Kataoka A; Ishida M; Murakami S; Ohno S
Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
[TBL] [Abstract][Full Text] [Related]
6. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
7. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
8. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
9. Current status of antibody therapy for breast cancer.
Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
[TBL] [Abstract][Full Text] [Related]
10. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
11. Growth factor receptors in breast cancer: potential for therapeutic intervention.
Nahta R; Hortobágyi GN; Esteva FJ
Oncologist; 2003; 8(1):5-17. PubMed ID: 12604728
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal antibodies and breast cancer. Current therapeutic progress].
Collignon J; Gennigens C; Rorive A; Coucke P; Lifrange E; Maweja S; Fillet G; Jerusalem G
Rev Med Liege; 2009; 64(5-6):279-83. PubMed ID: 19642459
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
15. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
Pegram M
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S121-30. PubMed ID: 18777951
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Spector N
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
[TBL] [Abstract][Full Text] [Related]
18. Successful targeting of ErbB2 receptors-is PTEN the key?
Crowder RJ; Lombardi DP; Ellis MJ
Cancer Cell; 2004 Aug; 6(2):103-4. PubMed ID: 15324690
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
Brufsky A
Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
